Oesophageal cancer: Assessment of response and follow up

Cancer Imaging

Volumn 7, Issue SPEC. ISS. A, 2007, Pages

  Rankin, Sheila C ^a,b  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

CT; Endoscopic ultrasound; Oesphageal cancer; Positron emission tomography; Recurrence; Response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE;

ARTICLE; AUTOPSY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE RISK; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; TUMOR VOLUME; DIAGNOSTIC IMAGING; DISEASE COURSE; ESOPHAGUS TUMOR; METASTASIS; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PREDICTION AND FORECASTING; REVIEW; SWALLOWING; TUMOR RECURRENCE;

COMBINED MODALITY THERAPY; DEGLUTITION; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 35848946363     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2007.9019     Document Type: Article

References (14)

1. Willis J, Cooper GS, Isenberg G, et al. Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma. Gastrointest Endosc 2002; 55: 655-61.
2. Chak A, Canto MI, Cooper GS, et al. Endosonographic assessment of multimodality therapy predicts survival of esophagpal carcinoma patients. Cancer 2000; 88: 1788-9S.
3. Walker SJ, Allen SM, Steel A, Cullen MH, Matthews HR. Assessment of the response to chemotherapy in oesophagcal cancer. Eur J Cardiothorac Surg 1991; 5: 519-22.
4. Duong CP, Hicks RJ, Weih L, et al. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in esophageal cancer. Eur J Nucl Med Mol Imaging 2006; 33: 770-8.
5. Griffith JF, Chan AC, Chow LT, et al. Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol 1999; 72: 678-84.
6. Beer AJ, Wieder HA, Lordick F, et al. Adenocarcinomas of esophagogastric junction: multi-detector row. CT to evaluate early response to neoadjuvant chemotherapy. Radiology 2006; 239: 472-80.
7. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692-8.
8. Flamen P, Van Cutsem E, Lerut T, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy for locally advanced esophagus cancer. Ann Oncol 2002; 13: 361-8.
9. Swisher SG, Maish M, Erasmus JJ, et al. Utility of PET, CT and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004; 78: 1152-60.
10. Carlisle JG, Quint LE, Francis IR, Orringer MB, Smick JF, Gross BH. Recurrent esophageal carcinoma: CT evaluation after esophagectomy. Radiology 1993; 189: 271-5.
11. Mariette C, Baton JM, Piessen G, Fabre S, Van Seuningen I, Triboulet JP. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer 2003; 97: 1616-23.
12. Katayama A. Mafune K, Tanaka Y, Takubo Y, Makuuchi M, Kaminishi M. Autopsy findings in patients after curative esophagectomy for esophageal carcinoma. J Am Con Surg 2003; 196: 866-73.
13. Flamen P, Lerut T, Van Cutsem E, et al. The utility of positron emission tomography (PET) for the diagnosis staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000; 120: 1085-92.
14. Kato H, Miyazaki T, Nakajima M, et al. Value of positron emission tomography in the diagnosis of recurrent esophageal carcinoma. Br J Surg 2004; 91: 1004-9.